Immutep (ASX:IMM) is entering an important phase of its development journey, as rising research spending and expanding clinical trials are reshaping both its financial results and its strategic outlook.

Neurizon Therapeutics (ASX:NUZ) has entered the second half of financial year 2026 in an acceleration phase, advancing its lead drug candidate while strengthening the financial and strategic foundations needed to bring it into late-stage development.

Acrux has returned to profitability for the first half of the 2026 financial year, reporting a significant improvement in performance as recently launched products delivered their first full revenue period.

Imugene (ASX:IMU) has reported a half-year shaped by tighter spending, renewed strategic focus and advancing clinical progress, as the company works to position its lead cell therapy program for the next stage of development.

The initiative is calling for expressions of interest from Australian small and medium enterprises, including start-ups and research spin-offs, that are developing medical devices to prevent, diagnose, treat, or manage heart disease and complications linked to both type 1 and type 2 diabetes.

Radiopharm Theranostics (ASX:RAD) has entered a significant new phase in its oncology program, announcing that the first patient has been dosed in a First-In-Human Phase 1/2a clinical trial of its experimental radiotherapeutic candidate, 177Lu BetaBart, also known as RV-01.

RNA therapy company PYC Therapeutics (ASX:PYC) has updated investors, confirming that it has concentrated on advancing its portfolio of first-in-class drug candidates, each intended to address the root cause of monogenic disorders.

Argent BioPharma (ASX:RGT) has marked a significant commercial step forward with the arrival of its largest-ever shipment of CannEpil in Ireland, signalling both expanding European market traction and the company’s growing operational scale.

Tetratherix (ASX:TTX) has released its half-year results for the 2026 financial year, with management saying the business remains on track across operations, finances and research as it moves from a research-focused company toward commercial growth.

Australia’s life sciences sector is set for a stronger, more coordinated innovation pipeline following a new national partnership between industry body AusBiotech and biomedical venture creator Proto Axiom.

Australia’s medical technology sector will take centre stage in May when AusBiotech brings its flagship AusMedtech conference to Perth for the first time.

CSL has taken another step in its push to expand its portfolio of innovative therapies, announcing a new licensing agreement with Eli Lilly that could broaden the future reach of its monoclonal antibody candidate, clazakizumab.

Medical Developments International (ASX:MVP) has reported a steady first-half performance for the financial year 2026, with growth in its flagship pain relief product helping to underpin revenue and cash flow despite softer conditions in its respiratory business.

Telix Pharmaceuticals (ASX:TLX) has taken another step in expanding its neuro-oncology portfolio, announcing the submission of a European marketing authorisation application for its brain cancer imaging candidate TLX101-Px.

Nyrada (ASX:NYR) has confirmed growing clinical momentum, strengthening finances, and expanding scientific validation for its lead candidate, Xolatryp, as the company positions itself for its next phase of development.

Australian pharmaceutical manufacturer IDT says it is beginning to show tangible signs of recovery after a period of leadership change and financial pressure, reporting improved earnings and renewed operational momentum in the first half of the financial year 2026.

Percheron Therapeutics (ASX:PER) is positioning itself as a small but strategically focused biotechnology company seeking to carve out a role in the rapidly expanding immuno-oncology market.

The life sciences sector will come together in March 2026 for a major show of support for women’s leadership, as AusBiotech and Medicines Australia expand their partnership to deliver both the long-running Women in Life Sciences Luncheon and, for the first time, a dedicated Leadership Summit.

Botanix Pharmaceuticals (ASX:BOT) has taken a major step to strengthen its commercial momentum and long-term manufacturing strategy, securing commitments for approximately $45 million in fresh capital as it looks to expand production, stabilise supply and accelerate growth of its lead dermatology product, Sofdra.